CT Financial Advisors’s Theravance Biopharma TBPH Stock Holding History

CT Financial Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$19.4K	Sell	528 -314	-37%	-$10K	0.01%	368
2016 Q4	$26.8K	Hold	842	–	–	0.02%	324
2016 Q3	$30.5K	Hold	842	–	–	0.02%	313
2016 Q2	$19.1K	Hold	842	–	–	0.01%	352
2016 Q1	$15.8K	Hold	842	–	–	0.01%	399
2015 Q4	$13.8K	Hold	842	–	–	0.01%	419
2015 Q3	$9.25K	Hold	842	–	–	0.01%	466
2015 Q2	$11K	Hold	842	–	–	0.01%	460
2015 Q1	$14.6K	Hold	842	–	–	0.01%	425
2014 Q4	$12.6K	Buy	+842	New	+$14.7K	0.01%	358

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

CT Financial Advisors's TBPH Position: Q1 2017 in Review

CT Financial Advisors reduced its Theravance Biopharma (TBPH) stake by 37% in Q1 2017, selling an estimated $10K and leaving 528 shares worth $19.4K. The position accounts for 0.01% of the portfolio, ranked #368.

CT Financial Advisors first reported a position in TBPH in Q4 2014 and has held it in 10 quarters since. The position peaked at $30.5K in Q3 2016. 92 funds tracked by Wall St. Rank hold TBPH as of Q1 2017.

CT Financial Advisors held 528 shares of Theravance Biopharma worth $19.4K as of Q1 2017.
CT Financial Advisors sold 314 Theravance Biopharma shares in Q1 2017, an estimated $10K.
Theravance Biopharma made up 0.01% of CT Financial Advisors's portfolio in Q1 2017, its #368 holding.
CT Financial Advisors first reported a position in Theravance Biopharma in Q4 2014 and has held it in 10 quarters since.
CT Financial Advisors's Theravance Biopharma position peaked at $30.5K in Q3 2016.
92 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2017.

Based on CT Financial Advisors's 13F filing for Q1 2017, filed 7 Apr 2017.